Bodhi has been contracted to run a baseline and endline evaluation of the four-year Gavi 5.0 Programme (2022-20260), the newest phase of a partnership between Girl Effect (GE) and Gavi between 2016 and 2021 on routine childhood immunisation and human papillomavirus vaccine demand generation. Bodhi will be evaluating GE's intervention and impact on drivers, intent and uptake of HPV vaccine for eligible girls and on drivers, intent and uptake of Routine Immunisation in target populations in both countries. We are collecting quantitative data against the baseline to offer a concrete understanding of programme's outcome, as well as qualitative data to evaluate the effectiveness, efficiency, impact and sustainability of the programme. Bodhi will also provide recommendations, capture lessons learned and highlight best practices for the next phase and for other similar programmes.